The Results Showed That Afamelanotide Could Improve Erythropoietic Protoporphyria

main points:

Q: in clinical practice, what is the relationship between afamelanotide therapy and erythropoietic protoporphyria (EPP) patients?

Conclusion: 117 patients with erythropoietic protoporphyria were included in the safety and efficacy test. The results showed that the increased outdoor time (6.1 hours / week) and quality of life score (14%) were related to the reduction of phototoxicity pain during the treatment with afamelanotide. Mild and self limiting adverse reactions such as nausea, fatigue and headache occurred.

Significance: conventional clinical practice has shown that alfanotide may be more effective than previous placebo-controlled trials in preventing phototoxicity.

The results of this study show that afamelanotide has good clinical efficacy and high safety in patients with erythropoietic protoporphyria.

From the clinical point of view, this treatment has a significant and continuous positive correlation with the quality of life, and is related to the prolonged duration of sunlight exposure and mild phototoxicity.